

Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

S. H. LEE¹, J.-J. YIM², H. J. KIM³, T. S. SHIM⁴, H. S. SEO⁵, Y. S. CHO⁵, H.-K. LEE¹,
Y. M. LEE¹, E. J. LEE⁶ AND W. J. LEW^{3,7*}

¹ *Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea*

² *Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, and Lung Institute, Seoul National University College of Medicine, Seoul, South Korea*

³ *Korean Institute of Tuberculosis, Seoul, South Korea*

⁴ *Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea*

⁵ *Seobuk Hospital, Seoul, South Korea*

⁶ *Public Healthcare Center, Seoul, South Korea*

⁷ *Stop TB and Leprosy Elimination, World Health Organization, Manila, Philippines*

(Accepted 12 July 2011; first published online 11 August 2011)

SUMMARY

We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST +/IGRA + ($n = 101$), TST +/IGRA – ($n = 22$), TST –/IGRA + ($n = 16$), and TST –/IGRA – ($n = 41$). RFP treatment (4 months) was prescribed only to the TST +/IGRA + group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST +/IGRA + subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.

Key words: Antibiotic prophylaxis, drug toxicity, multidrug-resistant tuberculosis, rifampicin, tuberculosis.

INTRODUCTION

Tuberculosis (TB) remains a significant global health issue, and is the single most important infectious cause of morbidity and mortality worldwide, with

approximately two million deaths and around nine million new cases each year [1–3]. In countries with a low or intermediate TB burden, the treatment of latent TB infection (LTBI) in order to prevent progression to active disease has been an essential strategic point for public health to eliminate TB [4, 5].

A small number of viable TB bacilli reside in an individual with LTBI without obvious clinical symptoms. Individuals with LTBI have normal chest

* Author for correspondence: W. J. Lew, M.D., Stop TB and Leprosy Elimination, World Health Organization, Office of the Representative, Bldg 3, DOH compound, Sta. Cruz, 1003 Manila, Philippines.
(Email: leww@wpro.who.int)

radiographs (CXRs), and tuberculin skin test (TST) has been the only tool to diagnose TB infection. Targeted TSTs select individuals at high risk of developing TB who would benefit from LTBI treatment [6].

Interferon-gamma release assays (IGRAs) are new tools for diagnosing LTBI which can be substituted for the TST [7, 8]; IGRAs can predict the subsequent development of active TB in recent TB contacts [9–11]. However, it is an important public issue with high priority to validate the role of TST and IGRA for the diagnosis of LTBI in contact investigation by determining the predictive value of positive test results [12] and rational strategy to select the indications for chemoprophylaxis [13], especially in intermediate TB burden countries like South Korea [1].

For LTBI treatment, rifampicin (RFP) is an alternative to isoniazid (INH) as a preventive treatment regimen [6], but the efficacy of RFP based on TST and IGRA results has rarely been reported. Although one study suggested superior safety of RFP compared to INH for preventive LTBI treatment [14], especially with respect to hepatotoxicity, and another study suggested a better compliance rate with RFP than INH prophylaxis [15], RFP also causes adverse events such as a flu-like syndrome [16] and immune-mediated thrombocytopenia [17]. Induction of drug resistance has also been reported [18, 19].

RFP prophylaxis was provided to TB contacts as part of a recent outbreak response in our previous report [20]. We evaluated the adverse events and relationship between contacts who developed TB and initial results from TB screening using TST and IGRA.

MATERIALS AND METHODS

We have previously reported the results of serial IGRAs after RFP prophylaxis in a TB outbreak in which five residents of a group home for people with learning disabilities had been sequentially diagnosed with active pulmonary TB in March 2007 [20]. The index case was diagnosed with bacteriologically confirmed laryngeal and pulmonary TB. Initially, a National TB Programme (NTP)-driven investigation of the outbreak with CXR screening was performed for all residents, and active TB was diagnosed in four patients with positive acid-fast bacillus (AFB) smears and in two patients with positive AFB cultures. The culture-positive patients had DNA genotypes with different patterns from the index case.

A *Mycobacterium tuberculosis* isolate was pan-susceptible to antibiotics, while another isolate was INH-resistant on conventional Löwenstein–Jensen medium. Faced with the persistent development of TB, the NTP performed TSTs and two IGRAs [QuantiFERON[®]-TB Gold In-Tube test (QFT-GIT), Cellestis Ltd, Australia, and T-SPOT.TB assay (T-SPOT), Oxford Immunotec, UK] simultaneously for all close contacts ($n=214$) in the facility.

For the analysis, subjects were divided into four groups according to the TST and IGRA tests results, as follows: TST+/IGRA+ ($n=101$), TST+/IGRA- ($n=22$), TST-/IGRA+ ($n=16$), and TST-/IGRA- ($n=41$). The IGRA results were considered positive if either the QFT-GIT or T-SPOT results were positive. RFP (450 mg/day for body weight ≤ 50 or 600 mg/day for body weight > 50 kg) was prescribed for 4 months in contacts with TST+/IGRA+ results according to the Korean guideline in 2007 [21]. In addition, RFP was prescribed for one contact who had two bacille Calmette–Guérin (BCG) scars and requested RFP prophylaxis on account of IGRA+ only. Medications were given daily under direct observation. By study protocol, all contacts who took RFP had blood tests (complete blood count, liver aminotransferase levels, and bilirubin level) before and after 1, 2, and 3 months of therapy with physical examinations, and CXRs were repeated every 3 months for 1 year and every 6 months for the following year.

We observed the development of new TB for about 2 years after the completion of treatment of LTBI as well as the adverse events during the prophylactic treatment. Adverse events were graded according to the grading systems [14] of the National Cancer Institute. The duration of follow-up was calculated as the period between the date of the positive TST test and the day of the last CXR or notification of TB development. The study was approved by the Institutional Review Board of the Korean Institute of Tuberculosis, and written informed consent was obtained from the study participants and their guardians.

TST and IGRA

A TST was performed using 2TU PPD RT23 (Statens Serum Institut, Denmark) and the Mantoux method. An induration size of 10 mm was adopted as the cut-off value. All subjects were examined with both QFT-GIT and T-SPOT assays according to the manufacturers' instructions.




Fig. 1. Flow diagram for 246 contacts of infectious patients with tuberculosis. TB, Tuberculosis; TST, tuberculin skin test; IGRA, interferon-gamma release assay; QFT-GIT, QuantiFERON-TB Gold In-Tube; T-SPOT, T-SPOT.TB; FU, follow-up. * One contact with no TST and IGRA + results received rifampicin prophylaxis.

Statistical analysis

All analyses were performed using SPSS software version 12.0 (SPSS Inc., USA). Comparisons between groups were made using the χ^2 and *t* tests for variables. All tests of significance were two-sided; *P* values < 0.05 were considered statistically significant.

RESULTS

Clinical characteristics

From the 246 members in the residential facility, 214 contacts were enrolled. Six contacts with bacteriologically confirmed active TB and 26 contacts with clinical pulmonary TB with abnormal CXRs were excluded (Fig. 1). All contacts had negative results

on human immunodeficiency virus tests. The clinical characteristics of the 214 subjects are presented in Table 1.

One hundred and forty (65.4%) contacts were males and 74 (34.6%) were females. The mean age of contacts was 41 years (range 16–70 years). One hundred and thirty-five (67.2%) contacts had BCG scars. The mean value of the TST induration size was 12.4 ± 7.2 mm (range 0–29 mm). The baseline CXRs of the 214 contacts were normal. The percentage of positive TSTs, QFT-GITs, and T-SPOTs were 67.7%, 56.7%, and 59.7%, respectively.

Of the 214 contacts, 180 had completed all TST, QFT-GIT, and T-SPOT tests and the kappa values between the TSTs and QFT-GITs, TSTs and T-SPOTs, and QFT-GITs and T-SPOTs were 0.55

Table 1. *Clinical characteristics of 214 contacts*

Clinical characteristics	Values (<i>n</i> =214)
Age, mean, years (range)	41 (16–70)
Gender (male:female)	140:74
BMI (kg/m ²), mean ± s.d.	21.8 ± 3.3
History of previous anti-TB treatment (%)	6/179 (3.4)
Staff: resident	90:124
Presence of a BCG scar (%)	135/201 (67.2)
TST (mm), mean ± s.d. (range)	12.4 ± 7.2 (0–29)
TST positive (≥ 10 mm) (%)	130/192 (67.7)
IGRA positive (%)	123/210 (61.2)
Positive QFT-GIT (%)	115/203 (56.7)
Positive T-SPOT (%)	120/201 (59.7)
Diabetes mellitus (%)	4 (1.9)
HIV positive	0 (0)

BMI, Body mass index; TB, tuberculosis; BCG, bacille Calmette-Guérin; TST, tuberculin skin test; IGRA, interferon-gamma release assay; QFT-GIT, QuantiFERON-TB Gold In-Tube; T-SPOT, T-SPOT.TB; HIV, human immunodeficiency virus.

($P < 0.001$), 0.54 ($P < 0.001$), and 0.87 ($P < 0.001$), respectively. The above 180 contacts were divided into four groups based on the TST and IGRA results, as follows: TST+/IGRA+ ($n = 101$); TST+/IGRA− ($n = 22$); TST−/IGRA+ ($n = 16$); and TST−/IGRA− ($n = 41$) (Fig. 1).

Before initiation of prophylactic treatment for 101 contacts with TST+/IGRA+, we excluded five contacts who had a prior history of TB, eight contacts who refused prophylactic treatment, and two contacts who transferred to another area. Prophylactic RFP treatment was provided for 87 contacts [TST+/IGRA+ ($n = 86$) and IGRA+ ($n = 1$)]. Of 86 contacts with TST+/IGRA+ results, 81 completed 4 months of RFP prophylactic treatment with good compliance. The remaining five TST+/IGRA+ contacts and another contact with only IGRA+ results interrupted RFP medication.

The non-prophylaxis group did not differ from the RFP completion group with respect to age, gender, underlying diseases, previous BCG vaccination, and duration of follow-up; there was a difference in the percentage of positive TST induration and positive IGRA, as shown in Table 2. Ninety-three (93.9%) of 99 contacts in the non-prophylactic group and 80 (98.8%) out of 81 contacts in the RFP completion group were followed. The mean time of follow-up was 21.0 ± 4.9 months for the non-prophylactic group and 22.8 ± 1.9 months for the RFP completion group from the initiation of RFP.

Adverse events of RFP prophylaxis

Of 87 contacts who initiated RFP treatment for LTBI, 21 (24.1%) developed adverse events, including one grade IV thrombocytopenia (Table 3). The reasons for interrupting RFP were grade I/II flu-like syndrome ($n = 3$), grade IV thrombocytopenia ($n = 1$), and self-withdrawal without specific adverse events ($n = 2$). The clinical features of 'flu-like illness' were arthralgias, myalgias and headache. One health-conscious contact with no TST and IGRA+ results who desired RFP prophylaxis complained of ecchymosis and petechiae involving the entire body after 3 months of RFP treatment. The event turned out to be a grade IV thrombocytopenia due to RFP, and the thrombocytopenia resolved after stopping RFP. As shown in Figure 2, based on the laboratory examination conducted every month during treatment in 87 prophylaxis participants, 10 (11.5%) symptom-free contacts had hepatotoxic adverse events, all within grade I/II toxicity, two (2.3%) contacts had grade I/II thrombocytopenia, and one (1.1%) contact had grade IV thrombocytopenia. All who experienced adverse events had no previous hepatic or haematological disease except diabetes mellitus or hypertension.

Development of active TB during follow-up

The mean duration of follow-up from initiation of prophylactic treatment was 21.8 months. Of 214 contacts, active TB developed in two contacts who had baseline TST+/IGRA+ results 3 and 20 months after completion of RFP treatment for LTBI (incidence rate in TST+/IGRA+, 11.0 cases/1000 person-years). One contact was confirmed as having multidrug-resistant (MDR)-TB by drug susceptibility testing. In the MDR-TB case the initial TST induration was 12 mm and QFT-GIT and T-SPOT were both positive. The initial TST in the other case of active TB was 21 mm and both IGRA tests were positive. Unfortunately, the MDR-TB isolate was not available and a DNA fingerprinting result could not be obtained. The MDR-TB patient was cured with 2 years of second-line anti-TB treatment and the other TB patient died of complications after surgery for intestinal obstruction unrelated to TB.

Of the 79 contacts in the other groups (TST− or IGRA−), none progressed to TB during a mean follow-up of 21 months (incidence rate, 0 cases/1000 person-years). Of the 10 TST+/IGRA+ contacts in whom RFP prophylaxis was not administered, none developed TB during a mean follow-up of 21 months.

Table 2. *Clinical characteristics of contacts with both valid TST and IGRA results*

Characteristics	Non-prophylactic group (<i>n</i> = 99)	Rifampicin completion (<i>n</i> = 81)
Mean age, years (range)	40 (16–69)	44 (25–70)
Gender (male:female)	56:43	65:16
Diabetes mellitus (%)	2 (2.0)	2 (2.5)
HIV (%)	0 (0)	0 (0)
Presence of a BCG scar (%)	67 (67.7)	51 (63.0)
BMI (kg/m ²), mean ± s.d.	21.4 ± 3.5	22.0 ± 3.0
TST positive (≥ 10 mm) (%)	57 (57.6)	81 (100.0) (<i>P</i> < 0.01)
IGRA positive (%)	36 (36.4)	81 (100.0) (<i>P</i> < 0.01)
QFT-GIT-positive (%)	29 (29.3)	78 (96.3)
T-SPOT-positive (%)	35 (35.4)	81 (100.0)
TST and IGRA positive (%)	20 (20.2)	81 (100.0) (<i>P</i> < 0.01)
Prophylaxis interruption (%)	5 (5.1)	0 (0)
Follow-up number (%)	93 (93.9)	80 (98.8)
Duration of follow-up		
Mean ± s.d., months	21.0 ± 4.9	22.8 ± 1.9
Total time, months	1956	1824
Incidence of TB, no. (%)	0 (0.0)	2 (2.5)

TST, Tuberculin skin test; IGRA, interferon-gamma release assay; HIV, human immunodeficiency virus; BCG, bacille Calmette-Guérin; BMI, body mass index; s.d., standard deviation; QFT-GIT, QuantiFERON-TB Gold In-Tube; T-SPOT, T-SPOT.TB; TB, tuberculosis.

Table 3. *Adverse events of rifampicin in subjects who initiated prophylactic treatment*

Adverse events	Prophylaxis participants (<i>n</i> = 87)
Gastrointestinal, <i>n</i> (%)	2 (2.3)
Flu-like syndrome, <i>n</i> (%)	5 (5.7)*
Dermatological, <i>n</i> (%)	1 (1.1)
Hepatotoxicity, <i>n</i> (%)	10 (11.5)
Haematological (thrombocytopenia), <i>n</i> (%)	3 (3.4)†
All adverse effects	21 (24.1)

* One contact had gastrointestinal and dermatological events simultaneously, and 3/5 discontinued medications due to flu-like syndrome.

† One contact with no tuberculin skin test and positive interferon-gamma release assay results had grade IV thrombocytopenia after 3 months of treatment, and discontinued the medication.

Of the 22 contacts in the TST + /IGRA – group, none progressed to active TB during a mean follow-up of 22 months. Of these contacts, 13 had strongly positive purified protein derivative (PPD) results with diameter > 15 mm. Of the 16 contacts in the TST – /IGRA + group, none progressed to active TB during a mean follow-up of 21 months. Of these 16 contacts,

11 had QFT-GIT+, 15 had T-SPOT+, and 10 patients had both IGRA tests positive. Of the 41 contacts in the TST – /IGRA – group, none progressed to active TB during a mean follow-up of 21 months.

DISCUSSION

Major adverse events and the development of MDR-TB after RFP preventive treatment of LTBI occurred.

Adverse events from RFP prophylaxis in our cohort were similar to those reported in a previous study. Aspartate aminotransferase (AST) abnormalities were 3.4%, and alanine aminotransferase (ALT) abnormalities were 6.9% within 2 months of RFP prophylaxis, compared to rates after RFP prophylaxis of 4.2% AST abnormalities and 6.0% ALT abnormalities in a previous study followed up to 2 months [14]. However, the hepatotoxic adverse events in our study were mild, all within grade I/II toxicity. The asymptomatic rises in AST and ALT did not require cessation of RFP treatment and they would not have been detected if liver aminotransferase levels had not been performed monthly.

Flu-like symptoms occurred in 5.7% of our study participants, compared to a previous report in which it occurred in 4% and 10% of TB patients treated




Fig. 2. Changes in platelet count ($n=3$) and liver aminotransferase levels ($n=10$) with abnormalities during 4 months of rifampicin (RFP) treatment. AST, Aspartate aminotransferase; ALT, alanine aminotransferase.

with RFP (600 mg twice weekly) [22], and in 0.26% of 20 667 patients with leprosy (600 mg/day, $n=54$) during 3 months of RFP treatment [23, 24]. Usually, flu-like symptoms consist of episodes of fever in association with rigors, headache, arthralgias and myalgias, and sometimes rhinorrhoea [24]. These symptoms are much more commonly observed in cases of intermittent or high-dose administration [24]. In our study, the prevalence of flu-like symptoms seems to be higher than those previously reported, even when RFP was administered daily. In most patients flu-like symptoms can be considered tolerable if not related to thrombocytopenia crises and acute renal failure [24].

One (1.1%) contact with only positive IGRA results who desired RFP prophylaxis developed grade IV thrombocytopenia compared to a previous study with 0.6% grade III thrombocytopenia [14]; in this case there was no clinical significance as it is known that patients may recover even if they manifest purpura or abnormal bleeding if RFP is stopped [17, 25].

In our study, 81 (94.2%) of the 87 contacts completed the LTBI treatment. The completion rate for 4 months of RFP treatment has been reported to be 91%, compared to 76% for 9 months of INH treatment, and the costs of INH treatment for LTBI was higher than RFP [15, 26]. Particularly, the efficacy of LTBI treatment with 4 months of RFP has not been thoroughly studied, even though the efficacy with INH can reach 90% if taken properly [27]. Only a few studies reported that the efficacy of 3 months of RFP was 63% [28], and no active TB cases occurred with

6–7 months of RFP treatment for LTBI [29, 30]. However, our study demonstrated about 97.5% efficacy with 4 months of RFP, suggesting that RFP might be more effective than INH in treating LTBI.

It is an important finding that no active TB cases developed in the TST+/IGRA- group, especially in patients with strongly positive PPD results, as well as in the TST-/IGRA+ group. The reported incidence rates of TB in contacts with TST+/IGRA+ were 3.0% (10/337) when 317/337 contacts received INH preventive treatment [9], and 9.8% (5/51) when <25 out of 51 contacts received INH preventive treatment [12]. Considering these reports, in our study, even though active TB developed in two (2.0%) subjects among contacts with TST+/IGRA+, there would probably have been more numbers of TB cases if RFP prophylaxis had not been administered.

RFP can be used as an alternative to INH for the preventive therapy of LTBI, even in populations with a significant incidence of INH-resistant disease [31], and in South Korea the drug resistance rate of INH in new patients is about 10% [32]. However, RFP as a prophylactic regimen must be used with caution because the failure of RFP preventive therapy with the development of RFP-resistant TB can occur [18, 19]. In our study, two cases of active TB developed in contacts who received preventive therapy with RFP in the TST+/IGRA+ group, including one MDR-TB case. The patient with MDR-TB initially had a normal CXR and was AFB smear-negative and culture-negative; her initial TST result was 12 mm with QFT-GIT+ and T-SPOT+, and her serial follow-up results for T-SPOT and QFT-GIT did not

convert. If the main reason for the development of drug-resistant TB in this case was failure to diagnose active TB initially, this case underscores the need for effective diagnostic strategies and tests such as a chest CT scan [33]. However, it is possible that this case was due to an exposure unrelated to the outbreak and RFP prophylaxis as a DNA fingerprinting result could not be obtained because the MDR-TB isolate was not available for further analysis.

There are some limitations to our study. First, it was not demonstrated by the RFLP method whether the patient's MDR-TB strain was the same pathogen as the index case. Second, in following NTP policies in which prophylaxis is mandatory after a TB contact investigation, we were unable to recruit a sufficient number of comparative subjects who did not initiate or complete RFP prophylaxis. Moreover, we could not trace the subjects who were lost because of transfer to another area. Last, the number of subjects was small and total duration of follow-up was short. In addition, this study was not a randomized controlled trial that compared INH with RFP, so we cannot be certain that RFP is superior to INH.

According to our data, adverse events due to RFP prophylaxis occurred with a non-negligible frequency, and active TB developed in 2.5% of treated LTBI subjects, even after prophylactic treatment with RFP. Further, because this study suggested the possible development of MDR-TB on exposure to an INH-resistant index case as in South Korea where INH resistance is prevalent, further prospective studies with more participants, long-term follow-up and genotyping are required to clarify these issues. In conclusion, adverse events and development of TB, including MDR-TB, remain concerns after RFP prophylaxis. Therefore a strategy based on TST and IGRA for preventive treatment in a TB outbreak should be thoroughly investigated.

DECLARATION OF INTEREST

None.

REFERENCES

1. **World Health Organization.** The global plan to stop TB 2011–2015. Geneva: WHO, 2010. Report No. WHO/HTM/STB/2010.2 (<http://www.who.int/tb/publications/2010/eng.pdf>). Accessed 3 January 2011.
2. **Corbett EL, et al.** The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Archives of Internal Medicine* 2003; **163**: 1009–1021.
3. **Dye C, et al.** Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. *Journal of the American Medical Association* 1999; **282**: 677–686.
4. **Broekmans JF, et al.** European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. *European Respiratory Journal* 2002; **19**: 765–775.
5. **Jasmer RM, Nahid P, Hopewell PC.** Clinical practice. Latent tuberculosis infection. *New England Journal of Medicine* 2002; **347**: 1860–1866.
6. **American Thoracic Society/Centers for Disease Control and Prevention.** Targeted tuberculin testing and treatment of latent tuberculosis infection. *American Journal of Respiratory and Critical Care Medicine* 2000; **161**: S221–247.
7. **Menzies D, Pai M, Comstock G.** Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Annals of Internal Medicine* 2007; **146**: 340–354.
8. **Pai M, Zwerling A, Menzies D.** Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Annals of Internal Medicine* 2008; **149**: 177–184.
9. **Bakir M, et al.** Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. *Annals of Internal Medicine* 2008; **149**: 777–787.
10. **Yoshiyama T, et al.** Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. *International Journal of Tuberculosis and Lung Disease* 2010; **14**: 819–827.
11. **Kik SV, et al.** Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. *European Respiratory Journal* 2010; **35**: 1346–1353.
12. **Diel R, et al.** Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with *Mycobacterium tuberculosis*. *American Journal of Respiratory and Critical Care Medicine* 2008; **177**: 1164–1170.
13. **Mori T, Harada N.** Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. *Kekkaku* 2005; **80**: 675–686.
14. **Menzies D, et al.** Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. *Annals of Internal Medicine* 2008; **149**: 689–697.
15. **Menzies D, et al.** Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. *American Journal of Respiratory and Critical Care Medicine* 2004; **170**: 445–449.
16. **Blumberg HM, et al.** American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

- American Journal of Respiratory and Critical Care Medicine* 2003; **167**: 603–662.
17. **Holdiness MR.** A review of blood dyscrasias induced by the antituberculosis drugs. *Tubercle and lung disease* 1987; **68**: 301–309.
 18. **Livengood JR, et al.** Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. *Journal of the American Medical Association* 1985; **253**: 2847–2849.
 19. **Balcells ME, et al.** Isoniazid preventive therapy and risk for resistant tuberculosis. *Emerging Infectious Diseases* 2006; **12**: 744–751.
 20. **Lee SH, et al.** Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. *Respiratory Medicine* 2010; **104**: 448–453.
 21. **Korea Center for Disease Control.** National guidelines for managing tuberculosis. KCDC guideline 2007, pp. 133–141.
 22. **Grosset J, Leventis S.** Adverse effects of rifampin. *Reviews of Infectious Diseases* 1983; **5**: S440–S450.
 23. **Blajchman MA, et al.** Rifampicin-induced immune thrombocytopenia. *British Medical Journal* 1970; **3**: 24–26.
 24. **Martnez E, Collazos J, Mayo J.** Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. *Medicine* 1999; **78**: 361–369.
 25. **Girling DJ.** Adverse reactions to rifampicin in anti-tuberculosis regimens. *Journal of Antimicrobial Chemotherapy* 1977; **3**: 115–132.
 26. **LoBue PA, Moser KS.** Use of isoniazid for latent tuberculosis infection in a public health clinic. *American Journal of Respiratory and Critical Care Medicine* 2003; **168**: 443–447.
 27. **Lobue P, Menzies D.** Treatment of latent tuberculosis infection: an update. *Respirology* 2010; **15**: 603–622.
 28. **Anon.** A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. *American Review of Respiratory Disease* 1992; **145**: 36–41.
 29. **Villarino ME, et al.** Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. *American Journal of Respiratory and Critical Care Medicine* 1997; **155**: 1735–1738.
 30. **Polesky A, et al.** Rifampin preventive therapy for tuberculosis in Boston's homeless. *American Journal of Respiratory and Critical Care Medicine* 1996; **154**: 1473–1477.
 31. **Nolan CM, et al.** Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. *American Review of Respiratory Disease* 1986; **133**: 431–436.
 32. **Bai GH, et al.** Trend of anti-tuberculosis drug resistance in Korea, 1994–2004. *International Journal of Tuberculosis and Lung Disease* 2007; **11**: 571–576.
 33. **Lee S, et al.** The role of chest CT scanning in TB outbreak investigation. *Chest* 2010; **137**: 1057–1064.